证券代码：300143 证券简称：盈康生命 投资者关系活动记录表 编号：2025-07 投资者关 系活动类 别 ☑ 特定对象调研 □分析师会议 □媒体采访 □业绩说明会 □新闻发布会 □路演活动 □现场参观 其他 （电话会议） 参与单位 名称及人 员姓名 南方基金 冯啸 秦乾一 张德曦 陈哲、东证资管 邹秉昂、华创自营 胡建东、易米基金 刘家曦、中泰证券 祝嘉琦 孙宇瑶 余燕伶、平 安证券 裴晓鹏、光大证券 吴佳青、中信证券 沈睦钧 王凯 时间 2025 年 9 月 11 日 地点 山东省青岛市崂山区海尔路 1 号盈康一生大厦 18 楼盈康生命科 技股份有限公司会议室 上市公司 接待人员 姓名 董事会秘书 刘泽霖 投资者关系总监 董丁梦 投资者关 系活动主 要内容介 绍 1、公司在 AI 医疗方面有比较长时间和广泛的布局，请具体介 绍下，以及从经营数据上看有哪些提升效果？ 回答：公司AI应用经历了1.0 阶段（统一整合旗下医院四大核 心系统，实现一体化整合，解决信息孤岛等问题）、2.0 阶段（建 设互联网医院平台，构建"线上+ 线下"一体化服务链，建设大数 据湖，搭建医院管理自日清平台）和AI 应用3.0 阶 ...

Core Viewpoint - 盈康生命 has demonstrated steady growth in a challenging industry environment, achieving a revenue of 843 million yuan, a year-on-year increase of 2.4%, and a net profit of 61.83 million yuan, up 12.8% [3] Group 1: Medical Services - The company is focusing on the construction of a tumor specialty service system integrated with artificial intelligence, transitioning from scale expansion to quality and efficiency [4] - The acquisition of Changsha Kexin Tumor Hospital enhances the company's tumor medical service capabilities in Central China, filling a strategic gap and potentially increasing future growth [5] - The tumor revenue from the medical services segment reached 214.95 million yuan, a year-on-year increase of 25.14%, with significant growth in outpatient visits and advanced surgical procedures [5][6] Group 2: AI Integration - 盈康生命 is one of the few medical groups to implement AI comprehensively, improving diagnostic efficiency and patient experience significantly [6][7] - AI applications have led to a 66% increase in image reading efficiency and a 300% improvement in follow-up efficiency for discharged patients, resulting in a high patient net promoter score (NPS) of 92.5% [7] Group 3: Medical Devices - The company is advancing its medical device segment through high-end upgrades and global expansion, achieving a 35% year-on-year increase in overseas revenue [8][9] - Key products have seen market share growth, with the infusion pump ranking third in the domestic market, and the company has established nine new overseas distributors [9] Group 4: Future Outlook - 盈康生命 is building a comprehensive health ecosystem through AI empowerment and industry collaboration, transitioning from a traditional medical service provider to a holistic health management platform [10]

Core Viewpoint - In a challenging industry environment, Yingkang Life (300143) has reported steady growth in its semi-annual results, with revenue of 843 million yuan, a year-on-year increase of 2.4%, and a net profit attributable to shareholders of 61.83 million yuan, up 12.8% [1] Group 1: Medical Services - The company is focusing on the construction of a tumor specialty service system and deep integration with artificial intelligence (AI), driving a transition from scale expansion to quality and efficiency in medical services [2] - The company has completed a comprehensive development path from the 1.0 stage of new technologies and equipment to the 3.0 stage of tumor ecological evolution, enhancing its competitive advantage in the "pre-diagnosis and treatment" chain [2] - The acquisition of Changsha Kexin Tumor Hospital is expected to enhance the company's tumor medical service capabilities in Central China and improve its national strategic layout [2] - The tumor revenue in the medical services segment reached 214.95 million yuan, a year-on-year increase of 25.14%, with significant growth in tumor outpatient visits and surgeries [3] Group 2: AI Integration - Yingkang Life is one of the few medical groups in the industry to achieve unified AI deployment, integrating AI technology into all aspects of medical services [4] - AI applications have significantly improved diagnostic efficiency, with reading efficiency up by 66% and patient wait times reduced by 2 days [4] - The company has achieved a patient net promoter score (NPS) of 92.5%, indicating high patient satisfaction with its services [4] Group 3: Medical Devices - The company is advancing product upgrades and global expansion in its medical device segment, achieving a "soft and hard integration" of the industrial chain [6] - Major products have seen market share growth, with the infusion pump's domestic market share exceeding 10%, ranking third [6] - Overseas revenue for medical devices has increased by 35%, with the addition of nine new overseas distributors across various regions [6] Group 4: Future Outlook - The company aims to deepen its tumor discipline construction and enhance regional medical center layouts, creating a comprehensive health ecosystem [7] - Through AI empowerment and industrial collaboration, Yingkang Life is transitioning from a traditional medical service provider to a comprehensive health management platform [7]

Core Insights - The company reported a slight increase in revenue and a significant rise in net profit for the first half of 2025, attributed to both external acquisitions and internal growth driven by AI technology [1][2]. Financial Performance - The company achieved a revenue of 843 million yuan, a year-on-year increase of 2.4% [1]. - The net profit attributable to shareholders was 61.83 million yuan, reflecting a year-on-year growth of 12.8% [1]. Business Segments - The medical services segment generated 653 million yuan in revenue, with the oncology business being a key growth driver, contributing 215 million yuan, a 25.14% increase year-on-year [2]. - The company completed the acquisition of a 51% stake in Changsha Kexin Tumor Hospital for 357 million yuan, enhancing its presence in the central China region [2]. Operational Efficiency - The overall expense ratio decreased by 2 percentage points, while the average service volume per employee increased by 10% [3]. - The company reported an average revenue per employee of 710,000 yuan, up 8.9%, and an average profit per employee of 52,600 yuan, up 20.2% [3]. Market Expansion - The overseas market revenue grew by 35% year-on-year, while the domestic market share also showed steady improvement [3]. - The company achieved significant milestones in product registration and certification, including the EU MDR certification for its third-generation digital mammography machine [3]. Strategic Focus - The company aims to diversify its product offerings across tumor prevention, diagnosis, treatment, and health management to reduce reliance on overseas markets [5].

Core Viewpoint - 盈康生命 reported a solid performance in the first half of the year, achieving revenue growth and net profit increase, indicating a trend of high-quality development in the company. Financial Performance - The company achieved operating revenue of 843 million yuan, a year-on-year increase of 2.4% [1] - Net profit attributable to shareholders reached 61.83 million yuan, up 12.8% year-on-year [1] - Deducting non-recurring gains and losses, the net profit was 60.59 million yuan, reflecting a year-on-year growth of 19.2% [1] - Gross margin improved by 0.5 percentage points, while expense ratio decreased by 2 percentage points, showcasing operational efficiency [1] Medical Services Development - The core business in medical services generated revenue of 653 million yuan, a year-on-year increase of 2.28% [2] - Revenue from oncology services reached 215 million yuan, growing by 25.14% year-on-year, with significant increases in patient visits and advanced surgical procedures [2] - The company has established a comprehensive service system covering early screening, diagnosis, mid-to-late stage treatment, and rehabilitation management [2] Strategic Expansion - The company expanded its regional presence by acquiring Changsha Kexin Tumor Hospital, enhancing its capabilities in minimally invasive tumor treatment [2] - The acquisition is expected to enrich the company's oncology pre-diagnosis and treatment ecosystem, providing additional growth momentum [2] Innovative Service Offerings - The company is focused on integrating medicine with new technologies and experiences to meet diverse health needs [3] - New services include weight loss, precision anti-aging, and international medical services, alongside the introduction of over 100 new clinical technologies [3] - The company has pioneered brain-machine interface applications in healthcare, achieving notable surgical outcomes in Parkinson's treatment [3] AI Integration and Efficiency - The company has implemented a "medical + AI" strategy, leading to significant improvements in service capacity and operational efficiency [4] - Key metrics include a 10% increase in per capita service volume and a 2 percentage point reduction in overall expense ratio [4] - AI technologies have reduced surgical complications by 10% and improved various operational efficiencies, including a 66% increase in imaging diagnosis efficiency [4] Market Growth in Medical Devices - The company achieved a 35% year-on-year growth in overseas medical device revenue, driven by strategic market expansion [5] - In the domestic market, the company has upgraded its products and channels, achieving over 40% coverage in top-tier hospitals [5] - The company’s infusion pumps and mammography equipment have gained significant market share, ranking third in their respective categories [5] Global Market Strategy - The company employs a "one country, one policy" strategy for overseas market expansion, enhancing user experience and product application [6] - New partnerships with nine overseas distributors have been established, expanding coverage across multiple global regions [6]